微小RNA在心肾综合征中的诊治进展

The progress of micro RNA in the diagnosis and treatment of cardiorenal syndrome

心肾交互性疾病即心肾综合征(cardiorenal syndrome,CRS)是一种由于心脏或肾脏中的一个器官出现急性或慢性功能不全从而导致另一器官同样出现急性或慢性功能紊乱的一种病理状态。虽然CRS目前的治疗手段已经在不断的改善,但是其难以兼顾心脏容量与肾脏灌注的缺点一直无法克服,从而导致了CRS预后差,病死率高。探寻CRS新的诊疗手段是目前的研究热点。近年来,大量有关微小RNA(micro RNA)在心血管及肾脏疾病中的调控作用研究表明,miRNA可以作为诊治心脏、肾脏相关疾病的生物标志物及治疗新靶点,为CRS的诊治提供了新的思路。

Cardiorenal syndrome(CRS)is a pathological state in which acute or chronic dysfunction occurs in one organ of the heart or kidney leads to acute or chronic dysfunction in another organ.Although the current treatment methods of CRS have been constantly improving,it is difficult to balance the cardiac volume and renal perfusion,resulting in the poor prognosis and high mortality of CRS.Therefore,there is an urgent need for the new and effective means to treat CRS.In recent years,a large number of studies on the regulatory role of microRNA(miRNA)in cardiovascular and renal diseases have shown that miRNA can be used as a biomarker and new therapeutic target for the diagnosis and treatment of heart and kidney related diseases,providing a new idea for the diagnosis and treatment of CRS.